Showing results (1-10 of 305) with videos related to
Sort By:
Pageof 31
Current Opinion in HIV and AIDS|November 7, 2015
Statistical issues in trials of preexposure prophylaxisDavid T Dunn, David V GliddenStatistical Communications in Infectious Diseases|August 31, 2019
The Connection between the Averted Infections Ratio and the Rate Ratio in Active-control Trials of Pre-exposure Prophylaxis AgentsDavid T Dunn, David V GliddenStatistical Communications in Infectious Diseases|July 26, 2022
Confidence limits for the averted infections ratio estimated via the counterfactual placebo incidence rateDavid T Dunn, Oliver T Stirrup, David V GliddenThe Lancet. HIV|October 31, 2020
A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trialDavid V Glidden, Oliver T Stirrup, David T DunnClinical Trials (London, England)|October 23, 2025
Sample size estimation for the averted events ratioDavid T Dunn, Oliver T Stirrup, David V GliddenBMC Medical Research Methodology|June 26, 2023
Interpretation of active-control randomised trials: the case for a new analytical perspective involving averted eventsDavid T Dunn, Oliver T Stirrup, Sheena McCormack, et al.The Lancet. HIV|June 13, 2018
The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agentsDavid T Dunn, David V Glidden, Oliver T Stirrup, et al.The Lancet. HIV|October 2, 2019
Mosaic effectiveness: measuring the impact of novel PrEP methodsDavid V Glidden, Megha L Mehrotra, David T Dunn, et al.Biometrics|June 20, 2002
Robust inference for event probabilities with non-Markov event dataDavid V GliddenCurrent Opinion in HIV and AIDS|October 1, 2019
Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxisDavid V GliddenPageof 31